injury') [1] . I/R injury is responsible for pathological events in a wide range of conditions; the most extensively studied of which is cardiac arrhythmia and arrest associated with myocardial ischemia and infarction [2] . Other forms of tissue injury are associated with ischemia of multiple organs and subsequent reperfusion injury when blood flow is restored. Moreover, the untoward effects of I/R are not only restricted to the specific tissue/organ undergoing the initial ischemia but also extend to include injury to other organs distant to the ischemic tissue as a result of mediator release into the bloodstream draining the revascularized tissues and subsequent transport to remote organs, so-called distant or remote organ injury. This phenomenon was studied in most tissues including gut [3], lung [4], liver [5], kidney [6], skeletal muscle [7], and heart [8].
INTRODUCTION
Ischemia and reperfusion (I/R) is a pathological condition characterized by an initial shortage of blood flow to an organ followed by the subsequent restoration of perfusion and concurrent re-oxygenation. Occlusion of the arterial blood flow, such as that happens as a result of an embolus, causes tissue hypoxia with subsequent metabolic and pathological changes. Surprisingly, restoration of blood supply and reoxygenation is commonly associated with activation of several pathways that lead to exacerbation of inflammatory response and profound tissue damage (called 'reperfusion 3 transplantation is the standard of care in patients with endstage liver disease (ESLD) and those with tumors of hepatic origin [9] . In Egypt, hepatitis C virus (HCV), and its longterm complications, is a major endemic health problem leading to ESLD. An Egyptian demographic health survey conducted in 2008 concluded that 14.7% of the population have been infected, making this the highest prevalence in the world [10] , with much higher rates at around 26% and 28% in the Nile Delta and Upper Egypt respectively [11] [12] .
The vast majority of these patients eventually require liver transplantation. In our University of Mansoura, Egypt, the [14] .
The overall aim of this review, however, is to provide insights into the mechanisms of liver I/R injury, indicating the potential role of oxidative stress, inflammatory cytokines, and the role of nuclear factor kappa beta (NF-κB) in the pathogenesis of liver I/R injury, and the protective factors/ pathways that may help to improve therapeutic regimens for controlling hepatic I/R injury during liver transplantation surgery. We take into consideration the major role of calcium ions and the renin-angiotensin system (RAS) in the process of I/R injury.
Types and stages of liver I/R injury
Ikeda and co-workers had previously described two major types of liver injury that are attributable to ischaemia-reperfusion in the rat model, the 'warm' and the 'cold' types [15] .
The 'warm' I/R injury, with the hepatocellular damage as the prominent feature, develops in situ during liver transplantation surgery or during various forms of shock or trauma, and might lead to liver or even multiorgan failure. The 'cold' I/R injury, with damage to hepatic sinusoidal endothelial cells (SEC) and disruption of the microcirculation as the prominent features, occurs during ex vivo preservation and is usually coupled with warm I/R injury during liver transplantation surgery.
Although initial cellular targets of the two I/R injury types might be different, they do share a common mechanism in the disease etiology; that is, local inflammatory innate immune activation. The activation of liver KC and neutrophils, the production of cytokines and chemokines, the generation of reactive oxygen species (ROS), increased expression of adhesion molecules and infiltration by circulating lymphocytes and/or monocytes are immunological cascades present in both types of I/R injury [16] . Schematic representation of these stages is presented in Fig 1. Most studies elucidated the mechanistic insights into the stages of liver I/R injury had been conducted on transgenic knockout models and in an in situ model of segmental hepatic warm I/R in mice [14, 17] . A clinically more relevant mouse model, combining cold and warm I/R injury components followed by liver transplantation, has only been established by Shen and co-workers in 2005 [18] . These studies have distinguished two distinct stages of liver I/R injury, with unique mechanisms of hepatic damage. The initial insult is an ischemic injury results from glycogen consumption, lack of oxygen supply which lead to mitochondrial dysfunction and ultimately to ATP depletion and hepatocyte cell death. The second is a reperfusion injury, which follows the ischemic injury and results primarily from an intense inflammatory immune response that includes both direct and 
Types of cell injury and death
There is evidence that hepatocytes and SEC are the two main cell types that are directly injured in both cold and warm I/R injury. Hepatocytes are more sensitive to warm ischemic injury (37 °C), while SEC are more sensitive to cold ischemia (4 °C) that occur in cold preservation of donor liver grafts before transplantation. Exclusive pathological injury of single cell type is not known [17] .
Although the causes of cell death are variable, the mode of hepatic cell death typically follows one of two patterns.
The first leads to a pathologic pattern of necrosis, the process of which is called "oncosis" or "oncotic necrosis". Oncotic necrosis is typically the consequence of acute metabolic distress resulting from IR. Apoptosis, in contrast, represents the implementation of a death program often initiated by quite specific stimuli [20] . Apoptosis leads to the systematic resorption of individual cells that minimizes inflammatory responses and leakage of cellular components into the extracellular space. Apoptosis and necrosis are usually considered separate issues, but an alternate view is emerging that apop-
The distinct stages of liver ischemia-reperfusion injury. Ischemic injury, a localized process of hepatic metabolic disturbances, results from glycogen consumption, lack of oxygen supply and ATP depletion. The cell death, activation of complement and mitochondrial reactive oxygen species (ROS) production all contribute to liver immune activation after reperfusion, which involves multiple liver cell types, including Kupffer cells (KC), natural killer (NK) T cells, and polymorphonuclear cells (PMNs). The ischemia-reperfusion-activated proinflammatory immune cascade sustains itself by recruiting peripheral immune cells from the circulation, and is responsible for the ultimate liver reperfusion injury [Reproduced from Zhai et al., 2012] .
tosis and necrosis are frequently the consequence of the same initiating factors and signaling pathways. Rather than being separate entities, apoptosis and necrosis in their pure form may represent extremes on a continuum of cell death [21] .
However, the relative contribution of necrotic and apoptotic cell death to the overall liver injury during hepatic I/R is still controversial. Apoptosis is an energy dependent process, so theoretically when there is excessive depletion of ATP, necrosis should predominate. Also, necrosis takes longer time to become evident, normally more than 3 h. This is challenging to demonstrate experimentally in vivo, as tissue ATP before and after reperfusion would need to be measured as well as the altered metabolic activity of the cell. Many of the same factors and pathways are involved in both types of cell death, so there is much overlap. A new term "necrapoptosis" [22] or "necroptosis" [23] has been coined to describe a process that begins with a common death signal and culminates in procedure is a very common method for examining DNA fragmentation that results from apoptosis. Although TUNEL is a very effective technique for apoptosis assay, one major limitation of this approach is that TUNEL detects apoptotic cells at the latest stage in the process. Varying levels of apoptosis and necrosis have been described in the literature for different ischemia reperfusion models, but these conclusions on the different degrees of apoptosis versus necrosis need to be interpreted carefully as most assay methods for apoptosis are relatively nonspecific [24] .
Mechanisms underlying liver I/R injury
The mechanisms of liver I/R injury have been extensively studied, but nevertheless remain generally unclear [25] . The factors/pathways implicated in the hepatic I/R injury process include anaerobic metabolism and acidosis, mitochondrial damage, oxidative stress, disrupted intracellular calcium overload, liver KC and neutrophils, and cytokines and chemokines. More importantly, an effective prevention or treatment method remains unavailable.
Anaerobic metabolism
Liver I/R injury exerts broad spectrum metabolic effects on the body. Immediately after arterial blood has been cut off the liver, the metabolic pattern is shifted from aerobic to anaerobic leading to stopping of mitochondrial oxidative phosphorylation of the hepatocytes and accumulation of acidic metabolites, such as H+ ions, lactic acid and ketone bodies [25] . When mitochondrial ATP is considerably depleted, all intracellular ATP-dependent metabolic and enzymatic functions are gradually ceased off. However, after the pH restore to normal values with reperfusion, activation of intracellular pH-dependent proteases and phospholipases takes place leading to more worsening of tissue damage. This is called the pH paradox [17] . The toxicity resulting from acidic environment and low ATP results also in disturbance of Na+ and calcium homeostasis, impairment of the cellular functions, signaling interactions, and sodium/potassium ATPase (Na+/ K+-ATPase), leading finally to mitochondrial damage and cell death [26] .
Mitochondrial dysfunction
The mitochondria are the place where oxidative phosphorylation mainly takes place. Many studies have shown that mitochondrial dysfunction plays a critical role in the process of hepatocyte damage after I/R injury [27, 28, 29] . Opening of a non-specific pore in the mitochondrial inner membrane that is called the mitochondrial permeability transition (MPT) pore is a critical event in the progression of cell death in response to I/R injury (also known as mitochondrial permealization). During the ischemic period, the inner MPT pore is kept quiescent being inhibited by the low pH. However, upon reperfusion, the huge increases in mitochondrial Calcium, coupled with excess formation of ROS, induce opening of the MPT pore [27] . The pore can pass any molecule < 1500 Dalton, and therefore, H+ ions can pass back into the matrix through this channel, thereby inhibiting electron transport and ATP synthesis [30] . In addition, water molecules enter the mitochondria under osmotic gradient causing the mito-chondria to swell and even rupture which leads eventually to hepatocyte cell death. The extent to which pores remain open correlates directly with the duration of ischemia and inversely with the recovery of cells. Agents or protocols that protect against MPT pore opening such as cyclosporin A [31] , melatonin [32] and edaravone [33] were shown to provide mitochondrial protection against reperfusion injury. In a recent review, Bernardia and Di Lisa have recently discussed the molecular mechanism of the mitochondrial permealization and its significance in cell response to ROS and ischemic injury [34] .
Oxidative stress
A substantial body of literature has shown that oxidative stress plays a crucial role in I/R injury [35] [36] [37] . Many highly reactive ROS molecules including superoxide anions, hydroxyl radicals, and peroxide hydrogen are generated during the period of hepatic I/R injury. These reactive molecules attack many cellular organelles, proteins, lipids, and nucleic acids leading to enzyme inhibition, mitochondrial instability and formation of deleterious lipid peroxides. ROS can also damage endothelial cells and destroy the integrity of the mi- Individual oxidation stress-related gene armamentarium has been also studied in hepatic I/R injury models [41] .
Microcirculatory dysfunction
Microcirculatory disturbance plays an important part in endothelial nitric oxide synthase (eNOS) [42] . Some studies have shown that carbon monoxide and NO, which are all vasodilators, are likely play a role in reducing the severity of liver I/R injury [25, 43] .
Cytosolic calcium overload
Physiologic intracellular calcium concentration is about 10-100 nM, which is 10,000 folds less than the extracellular concentration. This gradient is essentially maintained by four mechanisms: (1) the ATP-dependent transmembrane efflux pump; (2) the Na+/K+ mediated Na+/calcium exchange pump; (3) the ATP-dependent calcium stores present in the endoplasmic reticulum; and (4) the mitochondrial oxygen-dependent calcium pump [44] . Under ischemic conditions, the absence of oxygen stops oxidative phosphorylation and diminishes ATP, thereby, the energy source by which three of the four mentioned mechanisms that preserve hepatocellular calcium homeostasis is depleted. This, in turn, leaves nonselective cell membrane calcium entry channels unopposed, resulting in increase in calcium entry [45] . Mitochondrial sequestration, the last of the four mechanisms, subsequently overloads the mitochondria with calcium causing more inhibition of oxidative phosphorylation as oxygen levels are further depleted [46] . In addition, and as a consequence of ischemia, the cytosolic pH falls due to accelerated anaerobic glycolysis. In an attempt to reestablish normal pH, hepatic cells extrude H+ ions in exchange for Na+ via a NHE. The Na+ ions are then exchanged for calcium by another Na+/Calcium exchanger causing a net increase in cytosolic calcium [47] . Furthermore, endogenous release of cytosolic calcium stored in the endoplasmic reticulum is also enhanced through activation of ryanodine receptors [48] . Normally the level of calcium inside the mitochondria is low, but as cytoplasmic calcium increases, the mitochondria can act as a buffering box for the excess calcium [48] .
During overload, however, the mitochondrial Na+/Calcium exchanger is overwhelmed, allowing mitochondrial levels to become high enough to trigger activation of the MPT pore in the inner mitochondrial membrane with subsequent cell death by apoptosis or necrosis [27] . in rat liver I/R injury [53] . Other reports, however, suggest that the protective role of CCBs is not only due to preventing an increase in hepatic calcium concentration in parenchy-mal cells, but also seem to protect the liver from ischemic injury by acting on sinusoidal lining or vascular cells rather than on parenchymal cells [54] .
Hepatic tissue blood flow has been considered to play an important role in hepatic I/R events, and in liver transplantation, graft microcirculation failure is considered a major determinant of postischemic liver injury [16] . A previous study reported that amlodipine attenuated hepatic I/R injury by cytoprotective effects on parenchymal and non-parenchymal hepatocytes during both preservation and reperfusion by improvement of microvascular circulation and inhibition of mediator release [55] . Chin and co-workers have also reported that the protective effect of the calcium antagonist diltiazem in liver I/R injury was mainly due to improvement in microvascular circulation [56] . Other calcium channel antagonist verapamil was demonstrated to have a modest protective effect in hepatic I/R injury mainly by prevention early generation of ROS [57] .
On the other hand, systemic hypertension is a common complication after liver transplantation. Several studies have reported that about 50% or more of the liver transplant recipients develop hypertension [58] . Due to their significant vasodilatory effects attenuating the vasoconstriction and endothelin-1 induced by immunosuppressant treatment, CCBs have been commonly used for the treatment of hypertension in these patients [58] . According to a review published in 2011 on the management of hypertension in liver transplant patients, dihydropyridine CCBs, such as nifedipine, isradipine, or amlodipine, are preferable due to their least interaction with the cytochrome P450 enzyme system and, therefore, carry the minimal risk of potential disruption of immunosuppressant levels. The authors also concluded that for the treatment of de novo hypertension after liver transplantation, dihydropyridine CCBs should be used as first line drugs due to their potent vasodilatory effects [59] .
Role of Kupffer cells (KC) and neutrophils
Liver inflammation can be induced by I/R but it is typically 
Neutrophil infiltration occurs as a result of inflammatory responses to necrotic cells and release of mediators and ROS
by KCs and blocking of KCs activation by the use of gadolinium chloride or methyl palmitate could reduce acute liver cell injury caused by I/R [62] . The sequestration of innate immune cells occurs primarily during reperfusion, which restores the delivery of oxygen and neutrophils to the tissues. Although essential to support cellular metabolism, the flux of oxygen into the previously ischemic tissues fires the formation of ROS by enzymes such as XO and NADPH oxidase by the invading neutrophils which will then direct their cytotoxic armory at parenchymal cells causing reperfusion injury that exacerbates cell damage and death caused by the previous ischemia [60] .
Cytokines and downstream signaling
The complex relationship between cytokines and chemok- antagonist. These rats exhibited suppression of the increased TNF-α and neutrophil attracting chemokines [69] .
Not all inflammatory cytokines appear to be injurious in hepatic I/R injury. In agreement with this fact, Camargo and co-workers have early shown that IL-6 appears to play a protective role as evidenced by the finding of that I/R injury in livers of IL-6 knockout mice was more severe than in wild type mice. Administration of recombinant IL-6 to the knockout mice before ischemia restored the mild type injury patterns seen in wild type mice [70] . There is some evidence that IL-4, IL-10 and IL-13, all of which are anti-inflammatory cytokines, may also play a protective role in I/R
injury. An early study conducted on mice showed that IL-10 suppressed expression of TNF-α, NF-κB activation, and significantly reduced liver neutrophil recruitment, edema and cell injury following partial hepatic I/R injury [71] . A recent study performed with cerebral ischemia in IL-4 knockout mice which showed that IL-4 partially protects against ischemic brain injury in mice [72] . Chemokines, like cytokines, are a family of locally produced factors, but chemokines are smaller molecules, which act locally at site of inflammation to guide leukocyte chemotaxis. The chemokine, known as CXCL-10, was shown to contribute to liver I/R injury 1h after reperfusion onwards in association with activation of KCs and neutrophils and increased TNF-α and IL-1 release [73] . In agreement with this finding, a study conducted in 2009 has shown that activation of chemokine receptor type 2 contributes to liver injury during I/R and increase neutrophil recruitment [74] .
Role of NF-κB
NF-κB is a pleiotropic transcription factor which is present in almost all cell types and is present as a homo-or heterod- Inhibition of XO derived ROS generation in activated neutrophils by allopurinol was also shown to markedly diminish NF-κB activation and attenuate hepatic [78] and renal [79] I/R injury in rat models.
Adhesion molecules
The adhesion of neutrophils to hepatic parenchymal cells and SEC, and migration into liver tissue require sequential steps in which many adhesion molecules are involved. The selectin category of adhesion molecules (P, E and L-selectin) are expressed by SEC early in reperfusion to mediate adhesion of platelets and neutrophils. Studies have shown that P-selectin expression is raised 20 to 30 min after reperfusion [80] . Other researchers have suggested that E-selectin expression, and not P-selectin, is required for I/R injury to occur [81] . This is followed by stronger adhesion of leukocytes on SEC by upregulation of other adhesion molecules such as VCAM-1 and ICAM-1. By doing so, they migrate across the endothelium into the liver parenchyma enhancing ROS production and degranulation of cytoplasmic vesicles containing enzymes capable to degrade extracellular matrix and hepatocytes.
Role of Renin-Angiotensin System (RAS)
The implication of the renin-angiotensin system (RAS) in cardiac and renal pathology has been subject of substantial body of research, as it may synchronize fibrosis and tissue repair, and is consequently a goal for treatment with RAS blockers. In addition to the systemic RAS, many tissues and organs can express local functional RAS components that are regulated by incentives within the same organ. Recent research has pointed at the presence of local RAS in the liver, and its role in the pathogenesis of liver disease and fibrogenesis [82] . Both local and systemic RAS appear to play bimodal role in tissue remodeling and scarring, especially after injury [83] .
The 'classical' RAS includes principally angiotensin II (Ang-II), angiotensin-converting enzyme (ACE) and the Ang-II type 1 (AT1) receptor, and is responsible for, not only sodium homoeostasis and vasoconstriction by acting on vascular smooth muscle cells, but also has a role in inflammation, cytokine production, cell proliferation, and tissue repair. It is also involved in the pathogenesis of the metabolic syndrome through its effects on fat metabolism and insulin sensitivity [84] . Other components of the RAS that may mediate inflammation and fibrosis include the prorenin receptor, which is likely to have intracellular functions beyond its role as a receptor for renin and prorenin. Another 'alternative' RAS has been identified in both human and rodents. It consists of a structural homologue of ACE, named ACE2, which shares more than 40% structural similarity with ACE [85] . ACE2 is able to cleave both Ang-I to Ang-(1-9) and Ang-II to Ang-(1-7) respectively. Many effects mediated by Ang-(1-7) appear to oppose those of Ang-II and the AT1 receptors, and include vasodilation, improvement of endothelial function, inhibition of cell proliferation, and antithrombotic effects [86] . There is increasing evidence that Ang-(1-7), beside its effect on its specific Mas receptor;
it may also mediate part of its effects via the AT2 receptors. possibly through inhibition of TNF-α and ICAM-1 [91] . In another study, lisinopril could effectively attenuate liver I/R injury in rat model. The author concluded that this effect was possibly by improving nitric oxide availability and reducing oxidative stress [92] .
Treatment options to ameliorate I/R injury in liver transplantation
Pharmacological treatment is believed to be effective to reduce I/R injury in liver transplantation based on data avail- 
Antioxidants
Because of the strong evidence for the importance of ROS in hepatic I/R injury, a number of different intervention strategies have been successfully used in multiple models of warm and cold I/R injury.
Xanthine oxidase (XO)
This hypothesis was mainly based on XO being invoked as a critical source of ROS during I/R injury, and the protective effect of the XO inhibitor allopurinol [79] . Unfortunately, there are multiple reasons for the limited importance of this approach under clinically relevant conditions. First, the enzyme XO exists as xanthine dehydrogenase and the con- 
Glutathione (GSH)
The tripeptide glutathione (GSH), present in high concentrations in hepatocytes, is a highly effective antioxidant by serving as an electron donor. Intravenous infusion of GSH has been shown to protect against reperfusion injury following rat liver transplantation [94] . On the other hand, treat-ment with the cysteine derivative N-acetylcysteine (NAC) can increase intracellular GSH levels and strengthen the defense arsenal when given before liver I/R. Furthermore, clinical trials have reached phase IV for the use of NAC as a protective agent against both warm and cold ischemia during liver surgeries [95] . Gene transfer of glutathione synthesis components glutamine cysteine ligase catalytic subunit, glutamine cysteine regulatory subunit, and glutathione synthase are attractive options to protect against I/R injury by increasing intracellular GSH levels [96] .
Superoxide dismutase (SOD)
Administration of exogenous catalase or superoxide dismutase (SOD) was among earliest interventions as a pretreatment before ischemic injury. Consequentially, induction or maintenance of SOD levels has become another common explanation for mechanism of protection by numerous substances [97] . However, even intravenous administration of high doses resulted in only partial protection, largely due to poor bioavailability of the enzyme. Thus, potential antioxidant therapies using modified variants of SODs, or catalase, may be alternative option.
α-Tocopherol
α-tocopherol is a vitamin E analogue that is favorably absorbed in humans. In an early study, oral pretreatment with α-tocopherol attenuated I/R injury and lipid peroxidation and increased synthesis of ATP when compared to control mice. The effect on cellular ATP levels suggests that this treatment improved mitochondrial function. However, in a double-blind randomized placebo controlled trial, treatment with a full racemic mixture of α-tocopherol showed no reduction in clinical outcome [98] . A latest mixture composed of vitamin E, taurine, and GSH showed a reduction in hepatic I/R injury in rats [99] . This suggests that a combination of more than one antioxidant may be more effective than employing a single one.
Ischemic preconditioning
Ischemic preconditioning is probably the most common method investigated for reducing I/R injury. It relies on exposing the liver to a short period of ischemia then reperfusion before the real period of hepatic ischemia. Ischemic preconditioning has been shown to reduce inflammatory 
MPT pore prevention
As discussed in section 3.2., opening of MPT pore in the inner mitochondrial membrane is a critical event in mitochondrial toxicity and progression of cell death in response to I/R injury. A number of treatments have been tried to decrease MPT pore during I/R principally by preventing extracellular ROS generation, including administration of melatonin and edaravone [32] [33] . Edaravone is an intravenous drug that has been used to help people recover from stroke in Japan since 2001. In May 2017, edaravone was FDA approved to treat patients with amyotrophic lateral sclerosis (ALS) in the United States [104] . Although originally designed for use in ischemic stroke, the drug inhibited MPT pore formation and exerted good preservation of mitochondrial respiration potential and a reduction in mitochondrial swelling when given before I/R of liver [33] and brain [105] , most probably owing to its strong antioxidant properties.
Targeting inflammatory cytokines/chemokines
The protective roles of IL-4, IL-10, IL-12, IL-13 and IL-18, all of which are anti-inflammatory cytokines, have been investigated in animal models of liver I/R injury. A study performed on mice showed that injection of recombinant murine IL-10 after partial hepatic I/R injury suppressed expression of TNF-α, NF-κB and significantly reduced neutrophil recruitment, inflammation and hepatocellular injury. Viral gene transfer of IL-10 and injection of hypertonic saline solution which also increases IL-10 levels also reduced hepatic I/R injury. Xiong and co-workers have recently shown that IL-4 partially protects against ischemic brain injury in IL-4 knockout mice [72] .
A murine model was used to explore the role of IL-12 following hepatic I/R injury. Hepatic ischemia for 90 min followed by reperfusion for 4 h resulted in hepatocyte expression of IL-12. Hepatocellular injury, neutrophil recruitment, increased TNF-α and serum ALT were markedly reduced after administration of neutralizing antibody to IL-12 [106] .
The histamine agonist, dimaprit, also exerted protective ef- 
Interventions inhibiting NF-κB
The NF-κB is a key regulator of inflammatory cytokines in I/R injury. As mentioned earlier it is kept quiescent in resting cells by complexing with its specific inhibitory protein I-κB. This I-κB when become phosphorylated, it degrades away unmasking the binding sequence of NF-κB to be able to bind its specific site on DNA and affect gene transcription. Some therapeutic trials relied on prevention of NF-κB activation through inhibition of I-κB degradation in the setting of experimental myocardial infarction [110] . However, this approach warrants further investigation in the setting of transplantation. Another way to inhibit I-κB breakdown would be the inhibition of proteasomes responsible for its degradation and thus, termination of function, of specifically marked proteins. In hepatic, renal, as well as cerebral ischemia the respective injury could be prevented by administration of proteasome inhibitor lactacystin or its derivative PS519. Experimental protocols analyzing the effects of gene therapy such as interference with NF-κB translocation have been also introduced. However, all these approaches have not been yet translated into larger clinical trials. 
Interventions inhibiting adhesion molecules
Adhesion molecules, such as ICAM-1 and VCAM-1, are necessary for adhesion of neutrophils to liver cells and their infiltration into liver tissue. Experimental evidence suggests that a reduced expression of adhesion molecules ameliorates renal and hepatic I/R injury. In phase I and II study, an anti-ICAM-1 antisense-oligonucleotide was analyzed in order to prevent acute graft rejection. Unfortunately, the oligonucleotide did not further reduce the rate of acute rejections or improved graft survival as compared to a conventional immunosuppressive protocol [111] .
TBC-1269 is an investigational inhibitor of more than one selectin member (i.e. multiselectin inhibitor) that reduced serum levels of the pro-inflammatory TNF-α and augmented levels of the anti-inflammatory cytokine IL-10 after liver I/R [112] . The multiselectin inhibitor OC-229 also provided significant protection to the ischemic liver including reduction of NF-κB activation [113] . However, while anti-adhesion molecule targeted therapies show some promise in experimental organ transplantation, more data is still needed before the clinical significance of this therapeutic intervention can be examined.
